EGFR and cancer: In addition, NSC765598 displayed favorable properties as a drug lead compound and thus could be considered a novel small molecule with potential for multi-target inhibition of EGFR/iNOS/mTOR/TGFB1/FGFR/MAP2K1 and could serve as a lead compound for developing new therapeutics for cancer treatment.